Clinical Effectiveness of Choline Alphoscerate for Older Adults With Major Depression and Subjective Memory Complaints

Not Applicable

Not yet recruiting

• Conditions: Major Depression
• Interventions: Drug: Placebo; Drug: choline alphoscerate

• Registration Number: NCT05257902
• Lead Sponsor: Samsung Medical Center

Brief Summary

To evaluate the efficacy of choline alphoscerate on improving symptoms related to depression, anxiety, and subjective memory complaints compared to placebo in patients with Major Depressive Disorder(MDD) accompanied with subjective cognitive decline, who are over the age of 60.

Detailed Description

This clinical trial will include the participants over age 60, diagnosed as MDD under treatment of antidepressant longer than 1 month's period, assessed as Hamilton Rating Scale for Depression(HAM-D) ≥ 14, and Mini-Mental State Examination(MMSE) ≥ 20, and those who are accompanied with subjective memory complaints. The investigators will evaluate the clinical efficacy of symptomatic improvement in depression, anxiety, and subjective memory complaints. The investigators will assess these outcomes including memory function, depression, anxiety, and satisfaction on medication with scales comparing control group with treatment group under 8 weeks of medication.

This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy.

Participants in the treatment group will take the choline alfoscerate as adjunctive therapy with their own antidepressants. Participants in the control group will take the placebo, which would not affect their medical condition, for the adjunctive therapy is the choice of agreement between clinician and participants. If there is the necessity of change in antidepressant or of adjustment of their dosage, investigator can stop the clinical trial and proceed to another treatment.

Study Timeline

• Study First Submitted: 2022-01-17
• Status Verified: 2022-02
• Study First Submitted QC: 2022-02-16
• Last Update Submitted: 2022-02-16
• Study First Posted: 2022-02-25
• Last Update Posted: 2022-02-25
• Study Start: 2022-03
• Primary Completion: 2023-03
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1. Age ≥ 60 years
2. Diagnosed as MDD under the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and confirmed with MINI-Depression
3. HAM-D ≥ 14
4. MMSE ≥ 20
5. Who had continuous subjective memory complaints more than 6 months before the period of screening
6. Who had taking antidepressants longer than 1 month in the period of screening

Exclusion Criteria

1. Diagnosed as schizophrenia, bipolar disorder, PTSD, OCD or other significant mental disorder under the criteria of DSM-5 (only the participants who had depressive disorder, sleep disorder, and the anxiety disorder are allowed to be included)
2. Who have medically unstable disease (only the participants, who have diabetes mellitus or hypertension under control with stable medication for 3 months could be included)
3. Diagnosed as dementia or mild cognitive impairment
4. Participants who are already taking choline alfoscerate within 6 months of period
5. Participants who have been taking medication of antipsychotics (including quetiapine), mood stabilizer, cognitive enhancer including donepezil, rivastigamine, galantamine, and memantine within 1months.
6. Participants who had previous history of liver disease or renal disease
7. Participants who had allergic reaction to choline alfoscerate
8. Other specific condition, which could be inappropriate for the trial inclusion, under the judgement of the principal investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control Group	Placebo	Participants in the control group will take the placebo, which would not affect their medical condition, for the adjunctive therapy is the choice of agreement between clinician and participants. If there is the necessity of change in antidepressant or of adjustment of their dosage, investigator can stop the clinical trial and proceed to another treatment.
Treatment group	choline alphoscerate	Participants in the treatment group will take the choline alfoscerate as adjunctive therapy with their own antidepressants.

Primary Outcome Measures

Name	Time	Method
Change of the total score of Korean version of Perceived Deficits Questionnaire-Depression	between baseline and 8weeks	Change of the total score of Korean version of Perceived Deficits Questionnaire-Depression between the baseline and visit 5, higher scores mean a worse outcome

Secondary Outcome Measures

Name	Time	Method
The difference the score	between baseline and each 2weeks, 4weeks, 6weeks, 8weeks	The difference between baseline and each period of visit in the score of the Korea version of montreal cognitive assessment (K-MoCA)
The difference between baseline and each period of visit in the score of the Hamilton Rating Scale for Anxiety (HAM-A)	between baseline and each 2weeks, 4weeks, 6weeks, 8weeks	Hamilton Rating Scale for Anxiety (HAM-A), mild: below17 score, moderate: 18-24 score, severe: above 30 score
The difference between baseline and each period of visit in the score of the total score of Medication Satisfaction Questionnaire (MSQ)	between baseline and each 2weeks, 4weeks, 6weeks, 8weeks	total score of Medication Satisfaction Questionnaire (MSQ)
The difference between baseline and each period of visit in the score of the Hamilton Rating Scale for Depression(HAM-D)	between baseline and each 2weeks, 4weeks, 6weeks, 8weeks	Hamilton Rating Scale for Depression(HAM-D), normal: 0\~6 score, mild: 7\~18 score, moderate: 18-24 score, severe: above 25 score
The difference between baseline and each period of visit in the score of the first questionnaire of Memory Functioning Questionnaire (MFQ)	between baseline and each 2weeks, 4weeks, 6weeks, 8weeks	first questionnaire of Memory Functioning Questionnaire (MFQ)
The difference between baseline and each period of visit in the score of the total Geriatric Depression Scale (GDS)	between baseline and each 2weeks, 4weeks, 6weeks, 8weeks	total Geriatric Depression Scale (GDS), higher scores mean a worse outcome
The difference between baseline and each period of visit in the score of the Mini-Mental State Examination(MMSE)	between baseline and each 2weeks, 4weeks, 6weeks, 8weeks	Mini-Mental State Examination(MMSE)
assessement AE	between baseline and each 2weeks, 4weeks, 6weeks, 8weeks	collected all Adverse events